Compile Data Set for Download or QSAR
Report error Found 19 Enz. Inhib. hit(s) with all data for entry = 123
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181732(US9676728, 5 b (-)-2-(2,2,2-Trifluoro-1-(2-methoxy...)
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182861(US9676728, 11-B b (-)-2-(2,2,2-Trifluoro-1-methoxy...)
Affinity DataIC50: 55nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181734(US9676728, 6-A (-)-2-(2,2,2-Trifluoro-1-(2-methoxy...)
Affinity DataIC50: 380nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181724(US9676728, 3-B (-)-2-(2,2,2-Trifluoro-1-hydroxy-1-...)
Affinity DataIC50: 390nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182859(US9676728, 10-C (-)-2-(1-(5-Cyano-1H-benzo[d]imida...)
Affinity DataIC50: 470nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181709(US9676728, 2-C (-)-2-(1-Hydroxy-1-(2-methoxy-4,6-d...)
Affinity DataIC50: 1.45E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182856(US9676728, 9-C (-)-2-(Amino(cyclopropyl)(2-methoxy...)
Affinity DataIC50: 1.50E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181740(US9676728, 6-D (-)-2-(1-Amino-2,2,2-trifluoro-1-(2...)
Affinity DataIC50: 1.57E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181732(US9676728, 5 b (-)-2-(2,2,2-Trifluoro-1-(2-methoxy...)
Affinity DataIC50: 1.90E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181736(US9676728, 6-B (-)-2-(1-(3-Chloro-6-methoxy-2,4-di...)
Affinity DataIC50: 1.98E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181738(US9676728, 6-C (-)-2-(2,2,2-Trifluoro-1-(2-methoxy...)
Affinity DataIC50: 3.13E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181675(US9676728, 1-C (-)-2-(Hydroxy(2-methoxy-4,6-dimeth...)
Affinity DataIC50: 5.75E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182228(US9676728, 8-B (-)-2-(1-Amino-1-(2-methoxy-4,6-dim...)
Affinity DataIC50: 6.90E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181742(US9676728, 6-E (-)-2-(1-(3-Bromo-6-methoxy-2,4-dim...)
Affinity DataIC50: 7.00E+3nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182103(US9676728, 7-D (-)-2-(Amino(2-methoxy-4,6-dimethyl...)
Affinity DataIC50: 8.70E+3nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182866(US9676728, 12-D (B) (-)-2-(1-(2,6-dimethoxy-4-meth...)
Affinity DataIC50: 1.11E+4nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182865(US9676728, 12-D (A) (-)-2-((2,6-Dimethoxy-4-methyl...)
Affinity DataIC50: 1.39E+4nMpH: 7.4 T: 2°CAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 μM), recombinant human complement factor B (expressed in drosophila cells and purifi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM182861(US9676728, 11-B b (-)-2-(2,2,2-Trifluoro-1-methoxy...)
Affinity DataIC50: 4.11E+4nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM181729(US9676728, 4 (-)-2-(1-(3-bromo-6-methoxy-2,4-dimet...)
Affinity DataIC50: 9.89E+4nMpH: 7.4 T: 2°CAssay Description:Recombinant human factor B (expressed in drosophila cells and purified using standard methods) labeled with biotin (10 nM), europium-labeled streptav...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2018
Entry Details
Go to US Patent